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Abstract
Background: Sternocostoclavicular hyperostosis (SCCH; ORPHA178311) is a rare inflammatory disorder of the axial
skeleton, the precise pathophysiology of which remains to be established. We addressed the potential association
of SCCH with autoimmune processes by evaluating the lifetime prevalence of autoimmune disease in 70 patients
with adult-onset SCCH and 518 SCCH-unaffected first-degree relatives (parents, siblings and children). Danish
hospital registry data for autoimmune diseases were used as reference data.
Results: The mean age of interviewed patients was 56.3 years (range 26–80 years) and 86% were female. Interviewed
patients belonged to 63 families, with four families having clusters of 2–3 patients. A diagnosis of at least one
autoimmune disease was reported in 20 SCCH patients (29%) and in 47 relatives (9.1%), compared to an estimated 3.
9% prevalence of autoimmune disease in the Danish reference population. A diversity of autoimmune diseases was
reported in SCCH patients and relatives, most frequently psoriasis vulgaris (14%). Palmoplantar pustulosis was reported
by 28 patients (40%). In SCCH patients, inclusion of palmoplantar pustulosis as putative autoimmune disease increased
the overall prevalence to 54%.
Conclusions: The high prevalence of autoimmune disease in patients with sternocostoclavicular hyperostosis and their
first-degree relatives suggests that autoimmunity may play a role in the still elusive pathophysiology of the intriguing
osteogenic response to inflammation observed in this rare bone disorder.
Keywords: Sternocostoclavicular hyperostosis, Palmoplantar pustulosis, Autoimmune disease, Prevalence, Survey,
Inflammatory disease, SAPHO syndrome
Background
Sternocostoclavicular hyperostosis (SCCH; ORPHA178311)
is a rare inflammatory disorder of the axial skeleton, char-
acterized by chronic osteitis associated with a predomin-
antly osteogenic response. The disorder preferentially
affects the sternum, medial end of the clavicles and upper
ribs, and is often associated with a characteristic derma-
tosis: palmoplantar pustulosis (PPP), a chronic, sterile in-
flammation of the skin of palms and soles [1–3].
Clinical features of SCCH are pain and swelling of
the affected bones, with periods of exacerbation and
remission. The diagnosis is established on the basis of
characteristic scintigraphic and radiological features
(Fig. 1a–c). These consist of focal increases in radioisotope
uptake in affected bones on a technetium-99 m bone scin-
tigraphy (Fig. 1c) and of pathognomonic hyperostosis and
sclerosis in these bones on computed tomography (CT)
(Fig. 1a–b). Histological features are those of a chronic
osteomyelitis with inflammation and fibrosis of the mar-
row cavity, in the absence of an apparent pathogen
(Fig. 1d) [2–4].
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The inflammatory osteitis of SCCH is part of the
SAPHO syndrome (Synovitis, Acne, Pustulosis, Hyperos-
tosis and Osteitis; ORPHA793), which describes the vari-
able association of the skeletal manifestations of SCCH
with inflammatory joint manifestations, such as periph-
eral synovitis, and inflammatory cutaneous manifesta-
tions, such as palmoplantar pustulosis, severe acne,
hidradenitis suppurativa and pustular psoriasis [3–9].
SCCH is also part of the skeletal manifestations of
chronic recurrent multifocal osteomyelitis of children
(CRMO; ORPHA324964). Notwithstanding, the isolated
skeletal manifestation of SCCH (ORPHA178311) is also
recognized as a separate entity [1].
The precise pathophysiology of the chronic osteitis ob-
served in these syndromes remains elusive. There is, how-
ever, increasing evidence for a contributory role of
inflammatory, autoimmune and genetic factors in the
pathophysiology of the skeletal, articular and cutaneous
manifestations of these multi-faceted syndromes. Family
clustering has been reported for the SAPHO syndrome
[10–12] and for CRMO in children [13, 14]. We have ob-
served familial clustering for isolated adult-onset SCCH
(unpublished observations). There have also been a num-
ber of reports of family clustering of a variety of auto-
immune diseases in SAPHO and CRMO families [11–15].
Autoimmunity and autoinflammation have been shown to
be closely related and not to be mutually exclusive [16].
There is also evidence for a strong heritable component of
autoimmune diseases in general, with family clustering be-
ing a commonly observed phenomenon [17, 18].
The potential role of autoimmunity in the pathophysi-
ology of the osteoarticular and cutaneous manifestations
of SCCH and SAPHO has not been fully explored. How-
ever, an association between chronic inflammatory osteitis
and psoriasis, a chronic, immune-mediated inflammatory
skin disease has been consistently observed [6, 11, 19–21].
Moreover, palmoplantar pustulosis (which is frequently
present in SCCH patients) has been proposed to be an
autoimmune disease in its own right [22, 23].
To our knowledge, there has been so far no systematic
evaluation of general autoimmune comorbidity or of in-
creased prevalence of autoimmune disease in relatives of
patients with adult-onset SCCH. The objective of this
study was to determine the lifetime prevalence of auto-
immune disease in patients with adult-onset SCCH and
their first-degree relatives by means of a structured tele-
phone survey of index patients, during which information
was also collected on the prevalence of these disorders in
first-degree relatives. This approach may provide new
insights into the potential role of autoimmunity and
reinforce the evidence for genetic susceptibility in the
pathogenesis of the disorder.
Methods
We conducted a cross-sectional structured telephone
survey in patients with a diagnosis of adult-onset SCCH,
established on the basis of characteristic clinical, scinti-
graphic and radiological features. The majority of pa-
tients (81%) were identified from the Leiden University
Medical Center’s hospital registry. A minority of patients
(19%), not followed up in our out-patient clinic, but in
whom the diagnosis of SCCH was also confirmed, were
further recruited from the membership of the Dutch
SCCH Patients’Association (http://www.scch.nl).
Fig. 1 Characteristic radiological, scintigraphic and histological features of sternocostoclavicular hyperostosis in a 33-year-old woman with a
12-year history of SCCH. a Computed tomographic (CT) oblique sternal-coronal view of the sternocostoclavicular region showing the characteristic
sclerosis and hyperostosis of the medial end of the left clavicle with reactive joint changes corresponding to the site of increased radioisotope
uptake on skeletal scintigraphy. b Volume-rendered CT-scan showing the characteristic widening of the affected medial end of the left clavicle
due to hyperostosis. c Technetium-99 m skeletal scintigraphy showing intense uptake of the radioisotope in the left sternoclavicular region. d
Light micrograph of a biopsy of the bony lesion showing bony trabeculae with irregular kit-lines, with scattered lymphocytes and fibrosis of the
marrow (hematoxylin and eosin stain; front objective 10× magnification)
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All patients were contacted by telephone and invited
to take part in the survey. An appointment for the actual
telephone interview was made during this call, after ver-
bally obtaining the patient’s informed consent to take
part in the survey and to allow the use of additional clin-
ical information from their medical records. For patients
not followed up in our Center, written consent was add-
itionally obtained to request relevant medical informa-
tion from their treating physician.
The study was approved by the Medical Ethical Com-
mittee of the Leiden University Medical Center (Proto-
col registration number P08.112).
The interview was planned for a duration of 30–45 min
and structured to include questions relating to demo-
graphic details, relevant medical history including past
and present clinical manifestations of SCCH (pain, swell-
ing, local inflammatory changes, other), date of onset of
symptoms, date of diagnosis, investigations performed
and treatment received. A family pedigree, bridging three
generations was constructed with information on present
and past history of autoimmune disease, collected for the
patient as well as for affected or unaffected biological rela-
tives in the first degree: parents, full siblings and children.
The precise age of unaffected first-degree relatives was not
recorded.
Self-reported diagnoses of autoimmune diseases were
verified with information obtained from the patients’
medical records or from that obtained from the patients’
treating physicians in case the patient had never been
seen in our institution. Diagnoses reported by patients
for first-degree relatives were not cross-checked. Pathog-
nomonic features of palmoplantar pustulosis, a chronic
skin condition in which tiny sterile fluid/pus filled pus-
tules appear in waves of variable severity on one or both
palms and/or soles, were considered to be sufficiently
specific to warrant a diagnosis of the condition without
further confirmation. We considered a reported diagno-
sis for a patient or his or her first-degree relatives to rep-
resent an autoimmune disease when the diagnosis
corresponded to one of the 30 autoimmune diseases
listed by Eaton et al. in their 2010 publication on the
prevalence of 30 ICD-8 and ICD-10-classified auto-
immune diseases in Denmark [24]. Diagnoses reported
in first-degree relatives were discarded when too vague
to be reliably identified with a diagnosis on Eaton’s list
(for instance, we considered a reported diagnosis of
‘hypothyroidism’ without further specification as insuffi-
cient to be recorded as ‘autoimmune thyroiditis’). The
diagnosis “mixed connective tissue disease”, representing
a specific syndrome of a number of concomitant auto-
immune disorders, was added to Eaton’s list and studied
as a separate category.
To compare the prevalence of autoimmune diseases in
SCCH patients and their first-degree relatives to that of
the general population, we used the above-named
epidemiologic data from combined ICD-8 and ICD-10
hospital registrations in Denmark [24]. These data in-
clude lifetime prevalence estimates for 30 autoimmune
diseases, as well as an aggregate prevalence estimate
which corrects for individuals having a history of more
than one autoimmune disease [24]. Similar data on the
global epidemiology of autoimmune diseases are not
available for the general Dutch population. However, the
Netherlands and Denmark are culturally, ethnically and
socio-economically comparable, and the countries have
similar healthcare systems [25].
Statistical analysis
The primary outcome of the study was the overall life-
time prevalence of autoimmune disease in index patients
and their first-degree relatives. Prevalence was compared
between groups using the chi-square test. Mean values
between groups were compared using the unpaired t-
test. Comparisons with the general Danish population
were made using the one sample z-test. A significance
threshold of p < 0.05 was used. SPSS Statistics version 20
(Armonk, NY, United States: IBM Corp.) was used for
all analyses.
Results
Of 74 known patients with an established diagnosis of
adult-onset SCCH, three could not be contacted and
one declined to take part in the survey, so that a total of
70 patients were finally interviewed (Fig. 2). The 70
interviewed index patients reported data on 518 first-
degree family relatives unaffected by SCCH. The patients
belonged to 63 separate families, four of which had mul-
tiple affected family members. Three families had three
confirmed patients at the time of enquiry (mother, son
and daughter; brother and two sisters; mother and two
daughters), and one family had two confirmed patients
(mother and daughter).
Demographic characteristics
SCCH patients were predominantly female (86%) and had a
mean age of 56.3 ± 13.6 years at the time of the interview
(range 26–80 years). There was no significant difference in
age between interviewed men (mean age 53.8 ± 8.6 years)
and women (mean age 56.7 ± 14.3 years; p = 0.53).
Prevalence of autoimmune disease in index patients and
unaffected first-degree relatives
A history of at least one autoimmune disease was
present in 20 of the 70 patients (29%, 95% CI [19–40%])
and in 47 of the 518 first-degree relatives (9.1%, 95% CI
[6.9–11.9%]). The lifetime prevalence of autoimmune
disease did not significantly differ between men and
women, in patients (40% in men, 27% in women, p =
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0.39) or in their first-degree relatives (7.3% in men,
10.7% in women, p = 0.19).
In patients with SCCH, the most frequently encoun-
tered autoimmune disease was psoriasis vulgaris (14% of
patients), compared to a prevalence of 0.32%, 95% CI
[0.32%–0.32%] in the Danish general population [24]
(Table 1). In a separate analysis excluding psoriasis from
the list of autoimmune diseases, the prevalence of these
remained high with 17% of patients and 7.3% of relatives
with a history of at least one autoimmune disease other
than psoriasis. These figures are still significantly higher
than the reference prevalence in the general population
of 3.9%, 95% CI [3.92–3.96%], (p < 0.001) [24].
Four SCCH patients reported more than one diagnosis
of autoimmune disease. One patient had concurrent
diagnoses of psoriasis and rheumatoid arthritis. A sec-
ond patient had an autoimmune overlap syndrome with
concomitant diagnoses of mixed connective tissue dis-
ease and Sjögren’s syndrome. A third patient had a his-
tory of polymyalgia rheumatica and autoimmune
thyroiditis. A fourth patient had ankylosing spondylitis
and psoriasis.
Among first-degree relatives, two individuals had a
history of more than one autoimmune disease (Crohn’s
disease and rheumatoid arthritis in one, and auto-
immune thyroiditis and psoriasis in a second).
Prevalence of associated inflammatory conditions not
classified as autoimmune disease
A number of inflammatory conditions not classified as
autoimmune disease in Eaton’s listing were reported
during the survey. The most commonly reported inflam-
matory skin condition was the pathognomonic palmo-
plantar pustulosis in 28 index patients (40%) and nine
first-degree relatives (1.9%). Data on the prevalence of
this skin condition are not available for the general
population. Other inflammatory skin conditions re-
ported included severe acne on the anterior chest or
back (six patients and five relatives), pyoderma gangre-
nosum (one patient), hidradenitis suppurativa (one pa-
tient) and Jessner lymphocytic infiltrate (one patient).
One patient had a diagnosis of polyarteritis nodosa.
Löfgren syndrome (an acute variant of sarcoidosis) was
reported in a sibling of one of the patients.
Although none of the patients had a confirmed diag-
nosis of inflammatory bowel disease, non-specific gastro-
intestinal symptoms ranging from chronic diarrhea to
constipation were reported by 27 (39%) of the patients.
Effect of age on the prevalence of autoimmune disease
To evaluate whether a history of autoimmune disease
was associated with age in SCCH, we stratified patients
using the following age categories: below 40 years, be-
tween 40 and 60 years and 60 years and older. In the
youngest, middle and oldest strata, three out of seven
(43%), 10 out of 33 (30%) and seven out of 33 (23%) pa-
tients respectively had a history of autoimmune disease.
There was no significant difference between age groups
(p = 0.56).
To assess the effect of age on the prevalence of auto-
immune disease in first-degree relatives, we subdivided
individuals in this group into three generations, siblings
of patients (n = 256), parents (n = 126) and children (n =
136). In the parent, sibling and children generations, 13
(9.6%), 18 (7.0%) and 16 (12.7%) individuals respectively
had a history of autoimmune disease (Table 1). There
was no significant difference in prevalence of auto-
immune disease between generations in unaffected first-
degree relatives (p = 0.19).
Discussion
Our findings from this study demonstrate a relatively high
life-time prevalence of autoimmune disease in 29% of pa-
tients with adult-onset SCCH and in 9% of their first-
degree relatives, compared to prevalences varying from
3.2%, based on a literature review of studies published be-
tween 1965 and 1995 on 24 autoimmune diseases [13], to
3.9% based on national hospital registry data for 30 dis-
eases in Denmark [24]. The observed higher prevalence of
autoimmune disease is also higher than the prevalence of
7.6–9.4% as calculated after applying a correction to Eaton
et al.’s estimates for six diseases for which reliance on hos-
pital data may have produced an underestimation of true
prevalence (alopecia, celiac disease, hyperthyroidism,
hypothyroidism, psoriasis and vitiligo) [26].
Fig. 2 Flowchart of the patients included in the study
Valkema et al. Orphanet Journal of Rare Diseases  (2017) 12:20 Page 4 of 8
Our data support a tendency for autoimmune diseases
to occur at greater than expected rates in patients with
SCCH and their first-degree relatives. Although the in-
crease in the prevalence of autoimmune disease in our
cohort of patients was general, it was also heterogeneous
in nature, not appearing to be a uniform phenomenon
across all diseases (except for psoriasis, which was par-
ticularly prevalent, disproportionately contributing to
the excess prevalence of autoimmune disease in index
patients as well as in their first-degree relatives).
It is thought that autoimmune disease develops in gen-
etically susceptible individuals, with expression of the
disease modified by environmental factors [17]. Our
finding of clustering of autoimmune diseases in SCCH
patients and their first-degree relatives, although sug-
gesting the contribution of a general genetic background
of autoimmunity to the pathogenesis of this complex
disorder, does not necessarily imply a direct cause-effect
relationship between autoimmune diseases and SCCH.
Ultimately, other underlying factors may well be respon-
sible for both, although identifying such factors may
prove to be difficult.
The abnormal osteogenic response to inflammation
characteristic of SCCH is interestingly reminiscent of
that observed in the seronegative spondyloartropathy an-
kylosing spondylitis, with a number of studies currently
investigating the inflammatory and immune underpin-
nings of this disorder [27, 28].
An interesting hypothetical framework that may ex-
plain the association between inflammation and auto-
immunity can be found in the proposed immunological
“danger theory”, which emphasizes that autoimmune
disease can be provoked by cellular damage (“danger”)
signals [29, 30]. Within this context, it could be
Table 1 Prevalence of autoimmune diseases in SCCH patients and first-degree relatives
Patients Relatives Relatives per generation Denmarka
Child Sibling Parent
Total N 70 518 136 256 126 5 506 574
Female sex 60 (86%) 272 (52.5%) 69 (50.7%) 140 (54.7%) 63 (50.0%) 50.5b
Age (mean ± SD) 56.3 ± 13.6 ND ND ND ND 39.8b
Autoimmune diseases
Psoriasis vulgaris 10 (14%) 10 (1.9%) 4 (2.9%) 3 (1.2%) 3 (2.4%) 0.32%
Alopecia areata 0 2 (0.4%) 1 (0.7%) 1 (0.4%) 0 0.03%
Rheumatoid arthritis 2 (3%) 15 (2.2%) 1 (0.7%) 5 (2.0%) 9 (7.1%) 0.50%
Ankylosing spondylitis 2 (3%) 1 (0.2%) 0 0 0 0.07%
Polymyalgia rheumatica 1 (1%) 1 (0.2%) 0 0 1 (0.8%) 0.27%
Crohn’s disease 0 3 (0.6%) 1 (0.7%) 1 (0.4%) 1 (0.8%) 0.23%
Ulcerative colitis 0 4 (0.8%) 2 (1.5%) 2 (0.8%) 0 0.48%
Coeliac disease 0 3 (0.6%) 0 2 (0.8%) 1 (0.8%) 0.06%
Thyrotoxicosis 1 (1%) 2 (0.4%) 1 (0.7%) 1 (0.4%) 0 0.45%
Autoimmune thyroiditis 3 (4%) 1 (0.2%) 1 (0.7%) 0 0 0.06%
Diabetes mellitus type 1 1 (1%) 2 (0.4%) 2 (1.5%) 0 0 0.91%
Multiple sclerosis 0 2 (0.4%) 1 (0.7%) 1 (0.4%) 0 0.19%
Pernicious anemia 1 (1%) 3 (0.6%) 0 2 (0.8%) 1 (0.8%) 0.05%
MCD/overlap syndromec 1 (1%) 0 0 0 0 ND
Scleroderma 0 1 (0.2%) 0 0 1 (0.8%) 0.03%
Uveitis anterior 1 (1%) 0 0 0 0 0.21%
PPP (putative) 28 (40%) 9 (1.7%) 2 (1.5%) 6 (2.3%) 1 (0.8%) ND
Any autoimmune diseased 20 (29%) 47 (9.1%) 13 (9.6%) 18 (7.0%) 16 (12.7%) 3.9%
Any AID, including PPPd 38 (54%) 56 (10.8%) 15 (11.0%) 24 (9.4%) 17 (13.5%) ND
Any AID, excluding psoriasisd 12 (17%) 38 (7.3%) 10 (7.4%) 15 (5.9%) 13 (10.3%) ND
Abbreviations: SD standard deviation, ND no data, PPP palmoplantar pustulosis, MCD mixed connective tissue disease, AID autoimmune disease
aDanish general population prevalence data on 30 autoimmune diseases (from ICD-8 and ICD-10 codes), adapted from Eaton et al. [24]
bDemographic characteristics as of 1 January 2006 adapted from StatBank Denmark (http://statbank.dk/). Sex ratio and mean age respectively were retrieved from
the FOLK2 and GALDER datasets
cThis patient was analysed in a separate category; she had concomitant diagnoses of MCD and Sjögren’s syndrome
dReported figures take into account individuals with multiple diagnoses. Four patients and two relatives had two autoimmune diseases
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speculated that in SCCH patients, prolonged exposure
to low-grade inflammation combined with an inadequate
clearance of self-antigens from cellular debris may be as-
sociated with a state of increased susceptibility to auto-
immune disease in general.
Psoriasis is a chronic, immune-mediated inflammatory
skin disease estimated to affect about 2–4% of the popu-
lation in western countries. Our data on the high preva-
lence of psoriasis in adult-onset SCCH are in keeping
with those reported in patients with the SAPHO syn-
drome [11] and with data in children with CRMO [13].
The high prevalence of a specific autoimmune disease
such as psoriasis in affected as well as unaffected mem-
bers of SCCH families, in excess to that expected by
chance, may additionally offer insight into shared patho-
physiologic mechanisms that may lead to unraveling
shared etiological pathways.
Palmoplantar pustulosis was also frequently reported, al-
though its classification as an autoimmune disease is as
yet not widely accepted. Palmoplantar pustulosis was
originally believed to be a variant of psoriasis vulgaris
(to which it is closely related), although the condition
has distinct characteristics setting it apart from psoriasis
[31, 32]. The frequent occurrence of both psoriasis and
palmoplantar pustulosis suggests that these diseases may
be closely linked to the pathogenesis of SCCH. Further
understanding of the disease pathways involved in the
pathogenesis of these disorders will undoubtedly help to
delineate how exactly they may be interrelated.
An association has been previously reported between in-
flammatory bowel disease (IBD) and the SAPHO syn-
drome [13, 15, 33]. Intriguingly, none of our index SCCH
patients had a confirmed diagnosis of IBD, although non-
specific gastrointestinal symptoms were frequently re-
ported. Whereas, in our population, underdiagnosis of
IBD cannot be excluded, intestinal manifestations in
SCCH patients, albeit non-specific, may also represent an
independent inflammatory phenomenon outside the con-
text of IBD. Recent insights from the Pstpip2-deficient
mouse model suggest that this is plausible [34, 35]. In
these osteomyelitis-susceptible mice, alterations in the in-
testinal microbiota were thus found to accompany mani-
festations of inflammatory bone disease. Interestingly, a
change in dietary composition prevented both the micro-
biota changes and the inflammatory bone changes.
Our study has strengths as well as limitations. To our
knowledge, this is the first study addressing the preva-
lence of autoimmune disease in a cohort of patients with
adult-onset SCCH and their first-degree relatives. First-
hand information was available for all patients, the vast
majority of whom were diagnosed and followed up in
our Out-patient Clinic for a number of years. This
allowed us to verify the self-reported diagnoses of auto-
immune disease obtained during the telephone interview
with the patients’ medical records, providing some de-
gree of confidence on the accuracy and completeness of
the reported medical histories.
Our study has also a number of limitations. The data
obtained from SCCH patients about their unaffected
first-degree relatives are arguably less reliable, as not
verifiable. Unaffected family members were not separ-
ately contacted, and data provided by patients about
their relatives were not cross-checked with their medical
records. Notwithstanding, the process of systematic fam-
ily histories has been successfully used in the past to in-
vestigate familial clustering of autoimmune diseases [18].
We recognize that observational bias is a common
problem with retrospective surveys, and that such a bias
may have influenced our estimates. Misclassification may
have occurred due to misdiagnosis or underdiagnosis of
an autoimmune disease. It is also possible that some of
the reported diagnoses may have been based on criteria
established some years ago, which may be no longer valid
in the modern era. For example, a diagnosis of rheumatoid
arthritis established decades ago may need to be reap-
praised. It is also possible that the prevalence of SCCH it-
self could have been underestimated in our families–for
instance, family members with locomotor symptoms may
have undiagnosed SCCH. We have actually previously re-
ported on the frequent delay in diagnosing SCCH, which
could last for several years [36].
It has been argued that the figure of 3.9%, which we
have used in our study as reference value for the preva-
lence of autoimmune disease in the general population
[24], may be an underestimate of the true prevalence of
autoimmune disease, as it is based on Danish hospital reg-
istrations [26]. Nonetheless, the high lifetime prevalence
of autoimmune disease of 29% observed in SCCH patients
is sufficiently high to preclude it being a chance finding.
Another potential limitation in the interpretation of
our data is that our surveyed cohort of adult-onset
SCCH patients is relatively older than that of the re-
ported Danish general population (Table 1). However,
we found no significant association between age and the
prevalence of autoimmune disease in SCCH patients,
nor did we find significant inter-generation differences
in the prevalence of autoimmune diseases in first-degree
relatives of index patients.
Conclusions
Our data from this study demonstrate a high overall
prevalence of autoimmune disease in patients with
adult-onset SCCH and their unaffected first-degree
relatives and provide further evidence for the specific,
strong association of SCCH with palmoplantar pustu-
losis and psoriasis vulgaris. Whereas the association
between SCCH and autoimmune disorders shown in
our study is no proof of causality, this finding does
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raise the hypothesis of a potential role of a common
pathway for autoimmunity in the still elusive patho-
physiology of the intriguing abnormal osteogenic re-
sponse to inflammation observed in this rare bone
disorder.
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